Isis Innovation Limited

Btg International Limited

Glaxo Wellcome Inc.

University of Cambridge

British Technology Group Limited

Other

National Research Development Corporation

Burroughs Wellcome Co.

The Chinese University of Hong Kong

University College London

Cytomx Therapeutics, Inc.

Tolerx, Inc.

Tolerrx, Inc.

Btp International Limited

British Technology Group Intercorporate Licensing Limited

Herman Waldmann

Michael Ronald Clark

Mark Raymond Frewin

Paul J Fairchild

Frances Brook

Stephen Paul Cobbold

Richard Gardner

Scott David Gorman

Lisa K Gilliland

Gregory Paul Winter

Lutz Riechmann

Patricia Rao

Luis Richardo Simoes Da Silva Graca

Douglas Ringler

Stephen Cobbold

Dawn Winsor-Hines

Edward G Routledge

Masahide Tone

Sarah L Bolt

J Scott Crowe

Martin J Sims

Scott Gorman

Geoff Hale

Tadeusz Kornaga

Louise Walsh

Edward Graham Routledge

Anne Cooke

Geoffrey Hale

John Tite

Christine Hale

Oi Lan Kathy Lui

Scott Crowe

Martin Sims

Luis Richardo Da Silva Graca

Lisa Kim Gilliland

John Molecular Medicine Unit Isaacs

Geoffrey Therapeutic Antibody Centre Hale

The present invention provides for a novel method for inhibiting an undesirable immune response, especially in transplant recipients such as those having received an allogeneic stem cell transplant. Also disclosed are related compositions and kits for inducing immunotolerance.

Induction of immunotolerance to improve acceptance of tissue derived from pluripotent stem cells

A pharmaceutical comprising a therapeutic protein that binds to a therapeutic target, the protein being modified with a compound that inhibits binding of the protein to the therapeutic target, the modified protein being effective for reducing an immune response against the protein and for producing a therapeutic effect by binding to the therapeutic target. The therapeutic protein may be an antibody that includes an antibody combining site that binds to the therapeutic target.

Therapeutic antibodies

An altered antibody chain is produced in which the CDR's of the variable domain of the chain are derived from a first mammalian species. The framework-encoding regions of DNA encoding the variable domain of the first species are mutated so that the mutated framework-encoding regions encode a framework derived from a second different mammalian species. The or each constant domain of the antibody chain, if present, are also derived from the second mammalian species.

Altered antibodies and their preparation

Disclosed are embryonic stem cell-derived dendritic cells, genetically modified immature dendritic cells capable of maturation, as well as methods for the production of such cells. In one embodiment, the cells made be produced by a method comprising the steps of providing a population of embryonic stem cells; culturing the embryonic stem cells in the presence of a cytokine or combination of cytokines which brings about differentiation of the embryonic stem cells into dendritic cells; and recovering the dendritic cells from the culture. In a further embodiment, the cells may be genetically modified.

Method for producing dendritic cells

This invention relates to an antibody which is modified version of a therapeutic antibody with affinity for a cell-surface antigen, the antibody having reduced affinity for the antigen compared with the therapeutic antibody as a result of a modification or modifications to the antibody molecule, wherein the antibody is capable of inducing immunological tolerance to the therapeutic antibody. The invention further relates to a method of inducing immunological tolerance to a therapeutic antibody, comprising administering to a patient an antibody which is a modified version of the therapeutic antibody and which has reduced affinity for the antigen as compared with the therapeutic antibody.

Antibody variants

An IgG antibody is provided having a binding affinity for the CD3 antigen complex in which in the heavy chain has a variable region framework together with at least one CDR selected from the amino acid sequences of SEQ ID No 2, 4 and 6 and respective conservatively modified variants thereof and the light chain has a variable region framework together with at least one CDR selected from the amino acid sequences of SEQ ID No 8, 10 and 12 and respective conservatively modified variants thereof characterised in that the heavy chain variable region framework corresponds in sequence to the human type sequence and the light chain variable region framework includes one or more of the specific amino acids characteristic of the rodent type sequence. The novel antibody is capable of being expressed by mammalian cell expression systems at enhanced yields.

Humanized anti-CD3 antibodies

An IgG antibody is provided having a binding affinity for the CD3 antigen complex in which in the heavy chain has a variable region framework together with at least one CDR selected from the amino acid sequences of SEQ ID No 2, 4 and 6 and respective conservatively modified variants thereof and the light chain has a variable region framework together with at least one CDR selected from the amino acid sequences of SEQ ID No 8, 10 and 12 and respective conservatively modified variants thereof The novel antibody is capable of being expressed by mammalian cell expression systems at enhanced yields.

Methods of treatment using anti-CD3 antibodies

Inducing tolerance in a primate by use of a compound, or a combination of at least two compounds, that has certain characteristics when tested in vitro. The compound, alone or in combination, is preferably TRX1 antibody and the compound or combination is preferably used in accordance with a specified dosing regimen.

Compositions and methods of tolerizing a primate to an antigen

Anti-CD4 antibodies

Growing community of inventors

Oxford, United Kingdom

Herman Waldmann